Back to News
Market Impact: 0.2
Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?
Source: zacks.com
Analyst InsightsAnalyst EstimatesHealthcare & Biotech
Monte Rosa Therapeutics' consensus price target implies 152.9% upside, though the article cautions that this metric has limited predictive effectiveness. Upward earnings-estimate revisions may signal near-term upside for the stock, but no realized price move or forecast figure is provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
GLUE0.20
More News
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- UOB shares hit four-month low as Q3 profit misses analyst estimates
- Roku vp, cao Matthew Banks sells $86,906 in shares
- Palantir is dropping on earnings. Wall Street analysts remain bullish
- +49.6% since March: our AI-picked chipmaker keeps climbing after last week’s rout
- Midterm elections could jolt stocks if Democrats sweep Congress